Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Rhea-AI Summary
Dogwood Therapeutics (Nasdaq: DWTX) will report its first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets. Investors can expect a standard quarterly release and any accompanying investor materials or conference information to be shared around that time.
Positive
- None.
Negative
- None.
News Market Reaction – DWTX
In the May 7 session, DWTX declined 5.45%, reflecting a notable negative market reaction. Argus tracked a trough of -15.6% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Antiviral partnership | Positive | -8.5% | Global partnership with PRIDCor for IMC-1 and IMC-2 up to $100M. |
| Apr 15 | IND acceptance | Positive | -4.5% | FDA acceptance of SP16 IND for chemotherapy-induced pain and neuropathy. |
| Mar 18 | Earnings and funding | Neutral | -7.8% | Q4 and 2025 results with Halneuron® progress and financing extending cash runway. |
| Feb 02 | Trial enrollment | Positive | +5.0% | Over 50% enrollment and positive interim signals in Halneuron® Phase 2b trial. |
| Jan 12 | Equity financing | Negative | +5.6% | Dilutive registered and private offerings to raise up to $26.8M for Halneuron®. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often saw negative price reactions even to seemingly positive clinical and partnership updates, with only select pipeline/financing headlines drawing gains.
Over the past months, Dogwood has focused on advancing non-opioid pain assets and securing funding. A January financing of up to $26.9M supported Halneuron® Phase 2b development. Subsequent updates highlighted >50% enrollment in the Phase 2b trial and a partnership for antiviral assets worth up to $100M, along with IND acceptance for SP16 backed by a $2.5M NCI grant. Despite these milestones, most prior news days saw negative price reactions, framing today’s earnings-date announcement against a backdrop of volatile responses to developments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets.
About Dogwood Therapeutics
Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV.
Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron® is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (“CINP”). SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (LRP1) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b chemotherapy-induced pain and peripheral neuropathy trial is fully funded by the National Cancer Institute.
Dogwood Therapeutic’s largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.
Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
